Lerociclib: Experimental Treatment for Estrogen Receptor-Positive, HER2-negative (ER+, HER2-) Breast Cancer
Scientific rationale and therapeutic potential
Lerociclib is a potent and selective oral CDK4/6 inhibitor designed to block the proliferation of breast-cancer cells and induce tumor-cell death when combined with a selective estrogen receptor degrader (SERD), such as Faslodex®. Lerociclib has the potential to be best-in-class versus other oral CDK4/6 inhibitors.
Preclinical and clinical results (see: Publications)
- published preclinical data demonstrating lerociclib is more potent and has less toxicity than other oral CDK4/6 inhibitors in development;
- Phase 1 trial in 75 healthy volunteers demonstrated lerociclib was well tolerated with no grade 3/4 adverse events and no serious adverse events (view press release here).
G1 is recruiting patients for a Phase 1b/2a trial in ER+, HER2- breast cancer